IL6R and rheumatoid arthritis: Tocilizumab and sarilumab, both mAbs against IL-6R, have been approved for combination used with other types of antirheumatic agents or as monotherapy in patients with rheumatoid arthritis and other inflammation-related diseases.358 Tocilizumab and sarilumab were tested in clinical trials for their efficacy as rheumatoid arthritis treatments among patients with cardiovascular disease.359 Though tocilizumab significantly perturbs cholesterol and lipid homeostasis, including increasing TC and LDL, it also shows beneficial effects on surrogate markers of cardiovascular risk.